[Detection of serum S100 protein and tissue polypeptide-specific antigen for diagnosis and treatment of breast cancer].
To investigate the expressions of serum S100 protein and tissue polypeptide-specific antigen (TPS) in breast cancer and their clinical implications. Using enzyme-linked immunosorbent assay, the levels of serum S100 protein and TPS were determined in 48 breast cancer patients as well as in 92 control subjects. The median level of serum S100 protein and TPS were 0.024 microg/L and 135 U/L respectively in the 48 breast cancer patients, among whom their positive rates were 14.6% (7/48) and 50% (24/48) respectively; in stage IV patients, their positive rates were 70% (7/10) and 60% (6/10) respectively. The levels of the serum S100 protein and TPS tended to increase as the disease advanced, and serum S100 protein level was significantly higher in patients with distal metastasis than in those with local relapse of the tumor. Progressively elevated levels of serum S100 protein and TPS signify the deterioration of breast cancer, and can be used to estimate the stage and state of breast cancer.